NEW YORK – Proteomics firm Alamar Biosciences said Tuesday that it has entered a strategic partnership with Abcam.
Through the partnership, the companies aim to bring together Alamar's NUcleic acid-Linked Immuno-Sandwich Assay, or NULISA, proteomics platform and Abcam's extensive antibody portfolio to enable proteomic research.
Financial and other terms of the agreement were not disclosed.
Freemont, California-based Alamar closed an $80 million Series B funding round in September of last year. The company's NULISA platform uses sandwich immunoassays linked to nucleic acids allowing readout via next-generation sequencing. Additionally, Alamar has an antibody-development technology called Attobodies that it says allows it to obtain antibodies with picomolar affinities that can address challenging targets like G protein-coupled receptors and ion channels.
Cambridge, UK-based Abcam develops and sells a variety of life science reagents including a portfolio of more than 1,300 recombinant antibody pairs intended for biomarker discovery and research into the circulating proteome.
"Alamar is working to enable the early detection of cancer and other diseases by simultaneous measurement of hundreds to thousands of targets, even those present in minute amounts," Yuling Luo, founder and CEO of Alamar, said in a statement. "We are very happy to partner with Abcam to access their extensive portfolio of recombinant monoclonal antibody pairs, which will accelerate our ability to bring our proteomic discovery tools to researchers."
"We are excited to be partnering with Alamar as they develop an automated proteomics platform that has the potential to offer an unprecedented combination of sensitivity, plex-level and dynamic range," Emma Sceats, senior VP of sales, service, and business development at Abcam, said in a statement.